Cours Daiichi Sankyo Company, Limited Other OTC
Actions
DSNKY
US23381D1028
Produits pharmaceutiques
CA 2024 | 1 602 Md 10,25 Md 9,31 Md | CA 2025 * | 1 767 Md 11,31 Md 10,27 Md | Capitalisation | 10 394 Md 66,52 Md 60,41 Md |
---|---|---|---|---|---|
Résultat net 2024 | 201 Md 1,28 Md 1,17 Md | Résultat net 2025 * | 195 Md 1,25 Md 1,13 Md | VE / CA 2024 | 5,72 x |
Trésorerie nette 2024 * | 556 Md 3,56 Md 3,23 Md | Trésorerie nette 2025 * | 603 Md 3,86 Md 3,51 Md | VE / CA 2025 * | 5,54 x |
PER 2024 |
45,6
x | PER 2025 * |
52,8
x | Employés | - |
Rendement 2024 |
1,05% | Rendement 2025 * |
1,11% | Flottant | 97,04% |
Dernier transcript sur Daiichi Sankyo Company, Limited
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 01/04/07 |
Hiroyuki Okuzawa
PSD | President | 61 | 01/04/17 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 01/04/21 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 01/06/19 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 01/06/19 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 01/04/07 |
Varia. 1 janv. | Capi. | |
---|---|---|
+29,84% | 684 Md | |
+30,34% | 568 Md | |
-4,10% | 361 Md | |
+18,07% | 329 Md | |
+4,12% | 284 Md | |
+16,21% | 240 Md | |
+9,66% | 208 Md | |
-6,83% | 200 Md | |
+6,67% | 166 Md |